These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18385545)

  • 1. [Use of economic evaluation in the listing and pricing of pharmaceuticals].
    Lee TJ
    J Prev Med Public Health; 2008 Mar; 41(2):69-73. PubMed ID: 18385545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Guidelines for economic evaluation of pharmaceuticals in Korea].
    Bae EY
    J Prev Med Public Health; 2008 Mar; 41(2):80-3. PubMed ID: 18385547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current state and challenges of pharmacoeconomic evaluation in Korea].
    Choi SE
    J Prev Med Public Health; 2008 Mar; 41(2):74-9. PubMed ID: 18385546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System.
    Yoo SL; Kim DJ; Lee SM; Kang WG; Kim SY; Lee JH; Suh DC
    Int J Environ Res Public Health; 2019 Jan; 16(2):. PubMed ID: 30669602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Industry Survey on Unmet Needs in South Korea's New Drug Listing System.
    Kim S; Lee JY; Cho SH; Shin EJ; Kim M; Lee JH
    Ther Innov Regul Sci; 2023 Jul; 57(4):759-768. PubMed ID: 37183236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary.
    Lexchin J
    Health Policy; 2009 Jul; 91(2):142-7. PubMed ID: 19147251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
    Henry D
    Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Approaches to Drug Pricing.
    Kang SY; Bai G; DiStefano MJ; Socal MP; Yehia F; Anderson GF
    Annu Rev Public Health; 2020 Apr; 41():499-512. PubMed ID: 31874070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.
    Shiroiwa T; Fukuda T; Ikeda S; Takura T
    Health Policy; 2017 Aug; 121(8):836-841. PubMed ID: 28687183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways.
    Kim S; Cho H; Kim J; Lee K; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):119-126. PubMed ID: 32308058
    [No Abstract]   [Full Text] [Related]  

  • 15. Indication-specific pricing of pharmaceuticals in the US healthcare system.
    Pearson SD; Dreitlein WB; Henshall C; Towse A
    J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
    Robinson JC; Panteli D; Ex P
    Issue Brief (Commonw Fund); 2019 Feb; 2019():1-8. PubMed ID: 30883061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicines pricing singled out.
    Buchanan E
    S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941
    [No Abstract]   [Full Text] [Related]  

  • 19. Pricing schemes for new drugs: a welfare analysis.
    Levaggi R
    Soc Sci Med; 2014 Feb; 102():69-73. PubMed ID: 24565143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical Reference Pricing: Does It Have a Future in the U.S.?
    Robinson JC
    Issue Brief (Commonw Fund); 2018 Sep; 2018():1-6. PubMed ID: 30199167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.